Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: a pilot study.
Camila GiroAlayne M T D YamadaFelipe José S M CruzLilian A do R BarrosBeatriz da Costa Aguiar Alves ReisFernando L A FonsecaAuro Del GiglioPublished in: Breast cancer research and treatment (2024)
Evaluation of cfDNAI 2 weeks after NAC initiation appears to be an early biomarker for tumor pCR and DFS. Measuring Alu fragments of different lengths may replace techniques requiring prior tumor sequencing to measure ctDNA, reducing costs and complexity of cfDNA serial measurements in BC patients undergoing NAC.